Condition: Canavan Disease · Sponsor: Aspa Therapeutics
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
This description comes directly from the study's public registry record.
Alicia Gomez · 833-764-2267 or 617-861-4617 · CANaspire@aspatx.com
clinicaltrials@aspatx.com
Always discuss trial participation with your own doctor first.
| UCSF Benioff Children's Hospital Oakland | Oakland, California, United States | Recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| Massachusetts General Hospital (MGH); Center for Rare Neurological Diseases (CRND) | Boston, Massachusetts, United States | Recruiting |
| Weill Cornell Medicine; Division of Pediatric Neurology | New York, New York, United States | Completed |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04998396